Understanding how HIV resists treatment with broadly neutralizing antibodies
Defining the mechanisms of HIV resistance to bNAbs in humans
This study is looking at how HIV can dodge treatment with special antibodies that help fight the virus, so we can find better ways to help people living with HIV manage their condition more effectively.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rockefeller University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11075267 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which HIV can evade treatment with broadly neutralizing antibodies (bNAbs), which are a promising alternative to traditional antiretroviral therapy. The study aims to understand how the virus mutates and develops resistance to these antibodies, which could lead to more effective treatments. By analyzing the interactions between the virus and the immune response, researchers hope to identify strategies to enhance the effectiveness of bNAbs in controlling HIV infection. Patients may benefit from insights that could lead to improved therapies for long-term HIV management.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and may benefit from new treatment strategies involving bNAbs.
Not a fit: Patients who are not infected with HIV or those who are not currently receiving antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HIV, potentially allowing for long-term control of the virus without daily medication.
How similar studies have performed: Previous research has shown promise in using broadly neutralizing antibodies for HIV treatment, indicating that this approach has potential for success.
Where this research is happening
New York, United States
- Rockefeller University — New York, United States (Active)
Researchers
- Principal investigator: Caskey, Marina — Rockefeller University
- Study coordinator: Caskey, Marina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.